Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer
Authors
Keywords
Metronomic cyclophosphamide, PARP inhibition, DNA damage repair, BRCA, HR defect
Journal
INVESTIGATIONAL NEW DRUGS
Volume 34, Issue 3, Pages 355-363
Publisher
Springer Nature
Online
2016-03-21
DOI
10.1007/s10637-016-0335-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Profile of veliparib and its potential in the treatment of solid tumors
- (2015) Lars Wagner OncoTargets and Therapy
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2014) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Host Antitumor Immunity Plays a Role in the Survival of Patients With Newly Diagnosed Triple-Negative Breast Cancer
- (2014) Sherene Loi JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- Predictive biomarkers for cancer therapy with PARP inhibitors
- (2013) J Michels et al. ONCOGENE
- Advances in using PARP inhibitors to treat cancer
- (2012) Shivaani Kummar et al. BMC Medicine
- BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
- (2012) L Robertson et al. BRITISH JOURNAL OF CANCER
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
- (2012) M.-F. Langelier et al. SCIENCE
- Monitoring Drug-Induced H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
- (2010) L. H. Wang et al. CLINICAL CANCER RESEARCH
- Histone H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
- (2010) C. E. Redon et al. CLINICAL CANCER RESEARCH
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
- (2009) Shahneen K. Sandhu et al. EUROPEAN JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started